



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Our Ref.: 1038-517 MIS:as

In re

Application No.: 08/501,743

Applicant: Raafat E.F. Fahim et al

Title: ACELLULAR PERTUSSIS VACCINES AND METHODS OF PREPARATION THEREOF

Filed: July 12, 1995

Group No.: 1645

Examiner: A. Caputa

14/C
M.G.J
5/18/99
~~(NE)~~

May 12, 1999

AMENDMENT AFTER FINAL ACTION

BY COURIER

The Commissioner of Patents
and Trademarks
BOX AF,
Washington, D.C.
20231, U.S.A.

Dear Sir:

In response to the Final Action dated May 27, 1998, please amend this application in the following manner:

In the Claims:

Amend claim 27 as follows:

27. (Amended) A vaccine composition for protecting an at-risk human population against a case of the disease (whooping cough) caused by infection by *B. pertussis*, which comprises pertussis toxoid, filamentous haemagglutinin, pertactin and agglutinogens of *B. pertussis*, all in purified form, in selected relative amounts to confer protection to the extent of at least about 70% of members of the at-risk population.

OK
to enter
7-21-99
MM
Board Decision
9-10-04

REMARKS

In the Final Action, the Examiner rejected claims 27 to 39 under 35 USC 112, second paragraph, as being indefinite. In the Final Action, the Examiner indicated that it is unclear if the claimed compositions are intended to protect against only pertussis or other unspecified diseases.